194 related articles for article (PubMed ID: 21046425)
1. Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.
Macy ME; DeRyckere D; Gore L
Invest New Drugs; 2012 Apr; 30(2):468-79. PubMed ID: 21046425
[TBL] [Abstract][Full Text] [Related]
2. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
[TBL] [Abstract][Full Text] [Related]
3. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
[TBL] [Abstract][Full Text] [Related]
4. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Craveiro RB; Ehrhardt M; Velz J; Olschewski M; Goetz B; Pietsch T; Dilloo D
Oncotarget; 2017 Jul; 8(29):46915-46927. PubMed ID: 28159923
[TBL] [Abstract][Full Text] [Related]
5. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
Zage PE; Zeng L; Palla S; Fang W; Nilsson MB; Heymach JV; Zweidler-McKay PA
Cancer; 2010 May; 116(10):2465-75. PubMed ID: 20225331
[TBL] [Abstract][Full Text] [Related]
6. Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.
Jane EP; Premkumar DR; Addo-Yobo SO; Pollack IF
J Pharmacol Exp Ther; 2009 Oct; 331(1):327-37. PubMed ID: 19622715
[TBL] [Abstract][Full Text] [Related]
7. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
[TBL] [Abstract][Full Text] [Related]
8. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair.
Fan Z; Luo H; Zhou J; Wang F; Zhang W; Wang J; Li S; Lai Q; Xu Y; Wang G; Liang A; Xu J
Oncol Rep; 2020 Nov; 44(5):2152-2164. PubMed ID: 32901871
[TBL] [Abstract][Full Text] [Related]
11. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
12. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.
Flaig TW; Su LJ; McCoach C; Li Y; Raben D; Varella-Garcia M; Bemis LT
BJU Int; 2009 Jun; 103(12):1729-37. PubMed ID: 19220256
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.
Spanheimer PM; Park JM; Askeland RW; Kulak MV; Woodfield GW; De Andrade JP; Cyr AR; Sugg SL; Thomas A; Weigel RJ
Clin Cancer Res; 2014 Apr; 20(8):2115-25. PubMed ID: 24526731
[TBL] [Abstract][Full Text] [Related]
14. Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.
Monteverde M; Tonissi F; Fischel JL; Etienne-Grimaldi MC; Milano G; Merlano M; Lo Nigro C
Urol Oncol; 2013 Aug; 31(6):776-86. PubMed ID: 21795074
[TBL] [Abstract][Full Text] [Related]
15. KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
Nilsson MB; Giri U; Gudikote J; Tang X; Lu W; Tran H; Fan Y; Koo A; Diao L; Tong P; Wang J; Herbst R; Johnson BE; Ryan A; Webster A; Rowe P; Wistuba II; Heymach JV
Clin Cancer Res; 2016 Apr; 22(8):1940-50. PubMed ID: 26578684
[TBL] [Abstract][Full Text] [Related]
16. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Huang JJ; Li ZM; Huang Y; Huang Y; Tian Y; He XX; Xiao J; Lin TY
Invest New Drugs; 2012 Feb; 30(1):223-35. PubMed ID: 20960030
[TBL] [Abstract][Full Text] [Related]
17. The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
Yawata K; Osada S; Tanahashi T; Matsui S; Sasaki Y; Tanaka Y; Okumura N; Matsuhashi N; Takahashi T; Yamaguchi K; Yoshida K
Anticancer Res; 2016 Oct; 36(10):5215-5226. PubMed ID: 27798882
[TBL] [Abstract][Full Text] [Related]
18. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
19. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
[TBL] [Abstract][Full Text] [Related]
20. Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment.
Chu PL; Shihabuddeen WA; Low KP; Poon DJJ; Ramaswamy B; Liang ZG; Nei WL; Chua KLM; Thong PSP; Soo KC; Yeo ELL; Chua MLK
Photodiagnosis Photodyn Ther; 2019 Sep; 27():367-374. PubMed ID: 31299389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
